Emergent BioSolutions Inc.
EBSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 8, 2026
Scan Results
Daily timeframeEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States,. The $318.4M market capitalization puts EBS squarely in small-cap range for its industry. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Market Cap
$318.4M
Beta
2.34
P/E (TTM)
—
P/E (Fwd)
5.93
EPS (TTM)
$-3.41
EPS (Fwd)
$1.05
ROE
-40.3%
ROA
6.9%
Cash
$139.7M
Total Debt
$588.2M
Free CF
$37.5M
52W Change
-17.9%
Annual Financials
Cash vs Debt
Where EBS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, EBS finished 21.03% below its 150-day moving average ($8.18) and 28.78% below its 200-day moving average ($9.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EBS overbought or oversold?
At the September 3, 2026 close, EBS's RSI(14) was 90.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $139.7M in cash, though total debt stands at $588.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $37.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -40.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $1.64B (2021) to $705.2M (2025), a 57% decline worth watching.
A beta of 2.34 means EBS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Emergent BioSolutions Inc. and its sector.